Nuvectis Pharma, Inc. (NVCT) Balance Sheet
NVCT balance sheet, 2025
December 31, 2025 · U.S. dollars$31.7M assets = $13.3M liabilities + $18.4M equity
Both columns are drawn to the same scale: what NVCT owns equals what it owes plus shareholders’ equity. Hover a block for its value.
NVCT financial health
Descriptive bands, not a rating. Fiscal 2025.
NVCT balance sheet trends, 2020–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $6.7M2020 | $31.7M2025 | +36.6%/yr | |
| Total liabilities | $10,0002020 | $13.3M2025 | +321.4%/yr | |
| Shareholders’ equity | −$10,0002020 | $18.4M2025 | — | |
| Cash & short-term investments | $5.7M2020 | $31.6M2025 | +40.7%/yr | |
| Working capital | $5.8M2020 | $18.4M2025 | +$12.6M | |
| Book value per share | −$0.002020 | $0.842025 | — | |
| Current ratio | 583.302020 | 2.382025 | −580.92 | |
| Shares outstanding | 12.7M2020 | 21.8M2025 | +11.4%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
NVCT assets
NVCT liabilities and equity
NVCT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
NVCT balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & short-term investments | $31.6M | $18.5M | $19.1M | $20.0M | $5.7M | $5.7M |
| Cash & equivalents | $31.6M | $18.5M | $19.1M | $20.0M | $5.7M | $5.7M |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $75,000 | $74,000 | $59,000 | $412,000 | $91,000 | $91,000 |
| Total current assets | $31.7M | $18.6M | $19.2M | $20.4M | $5.8M | $5.8M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $824,000 | $824,000 |
| Total assets | $31.7M | $18.6M | $19.2M | $20.4M | $6.7M | $6.7M |
| Liabilities | ||||||
| Accounts payable | $6.3M | $2.5M | $2.8M | $2.9M | $1.1M | $10,000 |
| Total current liabilities | $13.3M | $8.9M | $7.0M | $6.2M | $2.4M | $10,000 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $0 | $2.9M | $15.2M | $10,000 |
| Total liabilities | $13.3M | $8.9M | $7.0M | $6.2M | $17.7M | $10,000 |
| Shareholders' equity | ||||||
| Common stock & paid-in capital | — | — | $17.77B | $14.75B | — | — |
| Retained earnings (deficit) | −$99.7M | −$73.2M | −$54.2M | −$32.0M | −$12.9M | −$10,000 |
| Accumulated other comprehensive income | — | — | — | −$14.75B | $0 | — |
| Total shareholders' equity | $18.4M | $9.7M | $12.2M | $14.2M | −$11.0M | −$10,000 |
| Key figures | ||||||
| Working capital | $18.4M | $9.7M | $12.2M | $14.2M | $3.4M | $5.8M |
| Tangible book value | $18.4M | $9.7M | $12.2M | $14.2M | −$11.0M | −$10,000 |
| Book value per share | $0.84 | $0.57 | $0.78 | $1.12 | −$0.87 | −$0.00 |
| Shares outstanding | 21.8M | 17.1M | 15.6M | 12.7M | 12.7M | 12.7M |
| Current ratio | 2.38 | 2.09 | 2.75 | 3.30 | 2.41 | 583.30 |
| Quick ratio | 2.38 | 2.08 | 2.74 | 3.23 | 2.37 | 574.20 |
| Equity / assets | 58.1% | 52.2% | 63.6% | 69.7% | −165.4% | −0.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $22.2M | $25.1M | $31.6M | $35.4M | $26.8M | $29.9M | $18.5M | $17.2M | $18.1M | $19.5M | $19.1M | $22.1M |
| Cash & equivalents | $22.2M | $25.1M | $31.6M | $35.4M | $26.8M | $29.9M | $18.5M | $17.2M | $18.1M | $19.5M | $19.1M | $22.1M |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $216,000 | $268,000 | $75,000 | $145,000 | $214,000 | $284,000 | $74,000 | $138,000 | $182,000 | $250,000 | $59,000 | $203,000 |
| Total current assets | $22.4M | $25.4M | $31.7M | $35.6M | $27.0M | $30.1M | $18.6M | $17.3M | $18.3M | $19.7M | $19.2M | $22.3M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $22.4M | $25.4M | $31.7M | $35.6M | $27.0M | $30.1M | $18.6M | $17.3M | $18.3M | $19.7M | $19.2M | $22.3M |
| Liabilities | ||||||||||||
| Accounts payable | $5.2M | $4.7M | $6.3M | $6.4M | $5.0M | $3.0M | $2.5M | $2.3M | $1.8M | $1.8M | $2.8M | $3.5M |
| Deferred revenue | $1.4M | — | — | — | — | — | — | — | — | — | — | — |
| Total current liabilities | $13.3M | $11.2M | $13.3M | $11.6M | $10.1M | $9.2M | $8.9M | $6.3M | $5.8M | $5.7M | $7.0M | $5.6M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total liabilities | $13.3M | $11.2M | $13.3M | $11.6M | $10.1M | $9.2M | $8.9M | $6.3M | $5.8M | $5.7M | $7.0M | $5.6M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | — | — | — | — | — | — | — | — | $18.65B | — | $17.77B | $17.33B |
| Retained earnings (deficit) | −$112.8M | −$105.7M | −$99.7M | −$92.4M | −$84.9M | −$78.6M | −$73.2M | −$67.0M | −$62.8M | −$58.4M | −$54.2M | −$47.6M |
| Accumulated other comprehensive income | — | — | — | — | — | — | — | — | — | $0 | — | — |
| Total shareholders' equity | $9.1M | $14.2M | $18.4M | $24.0M | $16.9M | $21.0M | $9.7M | $11.0M | $12.5M | $14.0M | $12.2M | $16.7M |
| Key figures | ||||||||||||
| Working capital | $9.1M | $14.2M | $18.4M | $24.0M | $16.9M | $21.0M | $9.7M | $11.0M | $12.5M | $14.0M | $12.2M | $16.7M |
| Tangible book value | $9.1M | $14.2M | $18.4M | $24.0M | $16.9M | $21.0M | $9.7M | $11.0M | $12.5M | $14.0M | $12.2M | $16.7M |
| Book value per share | $0.39 | $0.61 | $0.84 | $1.06 | $0.79 | $1.05 | $0.50 | $0.64 | $0.74 | $0.85 | $0.70 | $1.04 |
| Shares outstanding | 23.5M | 23.4M | 21.8M | 22.7M | 21.4M | 19.9M | 19.5M | 17.2M | 16.9M | 16.6M | 17.4M | 16.1M |
| Current ratio | 1.68 | 2.27 | 2.38 | 3.07 | 2.66 | 3.28 | 2.09 | 2.74 | 3.17 | 3.46 | 2.75 | 3.99 |
| Quick ratio | 1.67 | 2.25 | 2.38 | 3.06 | 2.64 | 3.25 | 2.08 | 2.72 | 3.14 | 3.42 | 2.74 | 3.96 |
| Equity / assets | 40.6% | 56.0% | 58.1% | 67.5% | 62.5% | 69.5% | 52.2% | 63.5% | 68.5% | 71.1% | 63.6% | 75.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 11, 2026); data from EODHD.
NVCT financial position
At the end of fiscal 2025 (December 31, 2025), Nuvectis Pharma had total assets of $31.7 million (up 70.4% from a year earlier), total liabilities of $13.3 million and shareholders' equity of $18.4 million. Its current ratio was 2.38. In the latest quarter (ended June 30, 2026) total assets were $22.4 million and equity $9.1 million.
Related: NVCT income statement, NVCT cash flow statement, NVCT key metrics. See the NVCT stock overview for the latest quote and news.
NVCT balance sheet FAQ
What are Nuvectis Pharma's total assets?
Nuvectis Pharma reported total assets of $31.7 million at the end of fiscal 2025 (December 31, 2025), compared with $18.6 million a year earlier.
How much cash does Nuvectis Pharma have?
Nuvectis Pharma held $31.6 million in cash and short-term investments at the end of fiscal 2025.
What is Nuvectis Pharma's book value?
Nuvectis Pharma's shareholders' equity (book value) was $18.4 million at the end of fiscal 2025, or $0.84 per share.
What is Nuvectis Pharma's current ratio?
Nuvectis Pharma had current assets of $31.7 million and current liabilities of $13.3 million, a current ratio of 2.38 (it can cover its short-term obligations).